Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
| ▸ | PIKFYVE | Q9Y2I7 | 1/20 | 0.31 |
| ▸ | ICMT | O60725 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9610093 | 0.80 | CYP3A4 (0.33) | CYP3A4 | |
| SCHEMBL9612037 | 0.78 | SMN1; SMN2 (0.35) | SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL13878792 | 0.78 | NPC1 (0.35) | — | |
| SCHEMBL9610122 | 0.70 | CYP2D6 (0.41) | SMN1; SMN2CYP3A4CYP2D6 | |
| SCHEMBL9610113 | 0.69 | CYP3A4 (0.41) | CYP3A4MAP3K14 | |
| SCHEMBL14282689 | 0.68 | TTBK1 (0.41) | SMN1; SMN2CYP3A4MAP3K14PIKFYVE | |
| SCHEMBL9610078 | 0.67 | CYP3A4 (0.37) | CYP3A4CYP2D6 | |
| SCHEMBL14355617 | 0.64 | MAP3K14 (0.33) | CYP2D6MAP3K14 | |
| SCHEMBL9610079 | 0.64 | GAA (0.38) | CYP3A4CYP2D6 | |
| SCHEMBL9912502 | 0.63 | CYP2D6 (0.47) | SMN1; SMN2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8198458-B2 | Non-nucleoside reverse transcriptase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-06-04 | — | — | US | disclosed |
| US-7517998-B2 | Benzothiazole or benzothiazine derivative of dipyrido(2,3;b:2',3'-e) diazepin-6-one; viricide against human t-cell leukemia/lymphoma virus | BOEHRINGER INGELHEIM INTERNATIONAL GMBH | 2009-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | SMN1; SMN2 1281/4885CYP3A4 2395/4885CYP2D6 1719/4885 |
| US-20090143370-A1 | Non-nucleoside Reverse Transcriptase Inhibitors | RTF1, POLR1A, POLR1E | SMN1; SMN2 1896/4885CYP3A4 673/4885CYP2D6 680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.